What's happening to the Medibank (ASX:MPL) share price today?

The private health insurer has made an announcement about its premiums

The Medibank Private Ltd (ASX: MPL) share price is seesawing today after the company said it would be deferring its premium increase.

At the time of writing, the private health insurance giant's shares are exchanging hands for $3.38, the same as yesterday's closing price. However, they have spent time in the red and the green today.

A doctor in a white coat with a stethoscope around her neck holds her hands upwards as if to ask 'why' as she sits at her desk and looks at her computer.

Image source: Getty Images

Medibank pushes back date on premium increase

According to the update, Medibank has returned roughly $135 million in COVID-19 savings to customers. This comes after it decided to defer next year's premium increase for 5 months.

Originally, Medibank and Ahm health insurance premiums were set to lift by an average of 3.1% from April 2022. The adjustment will be the lowest average premium increase in the last 21 years. However, this now won't happen until 1 September 2022.

The latest financial support package boosts the company's reputation in becoming socially responsible. So far, Medibank has returned about $435 million of relief to policyholders. However, the news hasn't done much for the Medibank share price.

Medibank CEO David Koczkar commented:

We have worked hard to deliver our lowest average premium increase in 21 years, recognising the importance of keeping private health insurance affordable.

While we know no one likes their premium to go up, healthcare costs are continuing to increase at a rate much higher than general inflation.

We support the Government's commitment to reform the prostheses list, which could save the industry up to $500 million, with savings expected to be realised over the next 4 years. We remain committed to passing on any related savings to our customers through lower premium increases and we will continue to advocate for changes that support the long-term sustainability and affordability of private health insurance.

Medibank share price snapshot

Over the last 12 months, the Medibank share price has been on par with the market, up 12%. In comparison, the S&P/ASX 200 Index (ASX: XJO) has also risen by 12% over the same time frame.

It's worth noting that Medibank shares reached a 52-week high of $3.62 in September, before moving in a sideways channel.

Medibank has a market capitalisation of roughly $9.3 billion, with approximately 2.75 billion shares on issue.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Could this ASX biotech really jump more than 80% in value?

This company's new technology has one broker impressed.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

CSL vs Pro Medicus: Which ASX healthcare share is better?

Both CSL and Pro Medicus have faced recent challenges but have enviable long-term track records. Here's which one I'd buy…

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

This ASX biotech could rise almost 50%, Morgans says

Turning science into contracts could unlock value for this company.

Read more »

Doctor with stethoscope using a tablet in a hospital.
Healthcare Shares

Telix Pharmaceuticals wins FDA Fast Track for BiPASS prostate cancer imaging

Telix Pharmaceuticals shares are in the spotlight after the FDA granted Fast Track for its BiPASS pre-biopsy prostate cancer imaging…

Read more »

Three scientists looking at a laptop in a lab.
Healthcare Shares

What would it take for CSL shares to return to $250?

The shares have already recovered strongly, so I wanted to see whether $250 is realistic.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Is the ResMed share price a cheap buy?

I look at what the next few years of earnings growth could mean for today’s valuation.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Expert names 'undervalued' ASX 200 healthcare stock to buy today

A top fundie expects more outperformance from this resurgent ASX healthcare share.

Read more »

A gavel is placed on a stand on a desk with a legal representative wearing a suit in the background.
Healthcare Shares

Cochlear shares fall as investors face another setback

Cochlear shares are back in the red.

Read more »